Alimera Sciences (ALIM) Misses Q1 EPS by 4c

Alimera Sciences (NASDAQ: ALIM) reported Q1 EPS of ($0.22), $0.04 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $5.83 million.

"In the U.S. we were pleased to see a record month for ILUVIEN® sales in March as well as almost twice as many first quarter benefit investigations as seen in the prior quarter," said Dan Myers, Alimera’s Chief Executive Officer. "We believe this is a sign of the increasing demand for ILUVIEN® in the U.S. and indicates that physicians are adopting ILUVIEN® into their treatment regimens. Furthermore, we have now surpassed 5,000 eyes treated with ILUVIEN® in the four countries in which we are commercialized."

For earnings history and earnings-related data on Alimera Sciences (ALIM) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c